Inozyme Pharma (Nasdaq:INZY) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

INZY 주식 개요

임상 단계의 희귀 질환 바이오 제약 회사인 이노자임 파마는 혈관, 연조직, 골격 질환 치료를 위한 새로운 치료제를 개발하는 데 주력하고 있습니다.

INZY 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

위험 분석

수익은 향후 3년간 연평균 0.8% 씩 감소할 것으로 예상됩니다.

수익이 1백만 달러 미만인 경우 ( $0 )

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

Inozyme Pharma, Inc. 경쟁사

XOMA

NasdaqGM:XOMA

US$275.7m

Enanta Pharmaceuticals

NasdaqGS:ENTA

US$274.7m

MeiraGTx Holdings

NasdaqGS:MGTX

US$270.7m

Amarin

NasdaqGM:AMRN

US$282.7m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Inozyme Pharma
과거 주가
현재 주가	US$4.46
52주 최고치	US$7.80
52주 최저치	US$2.69
베타	1.55
11개월 변경	-7.47%
3개월 변경 사항	-38.99%
1년 변경 사항	-19.93%
33년 변화	-73.76%
5년 변화	n/a
IPO 이후 변화	-74.57%

최근 뉴스 및 업데이트

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Apr 11

Recent updates

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Jul 19

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Jul 12

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Apr 06

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Dec 22

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Sep 08

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

May 22

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

May 07

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Feb 06

Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder

Jan 04

Inozyme Pharma (INZY) Investor Presentation - Slideshow

Dec 03

Inozyme Pharma EPS misses by $1.02

Nov 12

주주 수익률

	INZY	US Biotechs	US 마켓
7D	0.2%	-0.7%	0.07%
1Y	-19.9%	10.2%	20.7%

수익률 대 산업: INZY 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: INZY 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is INZY's price volatile compared to industry and market?
INZY volatility
INZY Average Weekly Movement	7.2%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.8%

안정적인 주가: INZY 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: INZY 의 주간 변동성( 9% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2015	59	Doug Treco	www.inozyme.com

임상 단계의 희귀 질환 바이오 제약 회사인 이노자임 파마는 혈관, 연조직 및 골격 질환 치료를 위한 새로운 치료제를 개발하는 데 주력하고 있습니다. 이 회사의 주요 제품 후보는 혈액 투석을 받는 말기 신장 질환 환자뿐만 아니라 ENPP1 및 ABCC6 결핍증 치료를 위한 용해성, 재조합, 유전자 조작, 융합 단백질인 INZ-701입니다. 이 회사는 예일대학교와 특정 치료 및 예방 제품에 대한 라이선스 계약을 체결했습니다.

Inozyme Pharma, Inc. 기본 사항 요약

Inozyme Pharma 의 수익과 매출은 시가총액과 어떻게 비교하나요?
INZY 기본 통계
시가총액	US$275.88m
수익(TTM)	-US$77.11m
수익(TTM)	n/a

0.0x

P/S 비율

-3.6x

P/E 비율

INZY 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
INZY 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$77.11m
수익	-US$77.11m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.25
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	37.9%

INZY 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

INZY 주식 개요

보상

위험 분석

Inozyme Pharma, Inc. 경쟁사

NasdaqGM:XOMA

US$275.7m

NasdaqGS:ENTA

US$274.7m

NasdaqGS:MGTX

US$270.7m

NasdaqGM:AMRN

US$282.7m

가격 내역 및 성능

최근 뉴스 및 업데이트

New major risk - Revenue and earnings growth

Price target decreased by 7.5% to US$19.43

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc., Annual General Meeting, Jun 18, 2024

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency (PXE) and ENPP1 Deficiency

Recent updates

New major risk - Revenue and earnings growth

Price target decreased by 7.5% to US$19.43

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc., Annual General Meeting, Jun 18, 2024

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency (PXE) and ENPP1 Deficiency

CEO & Chairman exercised options and sold US$52k worth of stock

New minor risk - Share price stability

Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency

New major risk - Revenue and earnings growth

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions

Inozyme Pharma, Inc. Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

New minor risk - Share price stability

Price target decreased by 9.3% to US$20.50

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $60 million.

Price target increased by 8.5% to US$22.60

Inozyme Pharma, Inc. Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in Phase 1b Trial of INZ-701

Insufficient new directors

Price target decreased by 13% to US$19.17

Inozyme Pharma, Inc. Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

Price target increased by 8.5% to US$21.80

Inozyme Pharma, Inc. Provides Business Updates

Inozyme Pharma, Inc. Announces First Self-Administration of Inz-701 in Ongoing Enpp1 Deficiency Phase 1/2 Clinical Trial

Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database

Price target increased to US$23.20

Inozyme Pharma GAAP EPS of -$0.38

Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Index

Inozyme Pharma, Inc. Appoints Kurt Gunter as Chief Medical Officer

Price target decreased to US$29.40

Inozyme Pharma, Inc. Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

Price target decreased to US$30.00

Inozyme Pharma, Inc. Announces Management Changes

High number of new directors

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Price target decreased to US$32.25

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Growth Index

President exercised options and sold US$65k worth of stock

Inozyme Pharma, Inc. Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of Inz-701 in Abcc6 Deficiency

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Senior Vice President of Finance Stephen Basso has left the company

Inozyme Pharma, Inc. Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

Member of Scientific Advisory Board has left the company

Member of Scientific Advisory Board has left the company

Member of Scientific Advisory Board has left the company

New 90-day low: US$19.96

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Inozyme Pharma Announces Executive Changes